Emergent Biosolutions, Inc. EBS
Analyst Ratings
- Consensus
- Hold — 1 Buy · 0 Hold · 1 Sell (2 analysts)
- Avg. Price Target
- $10.00 (+60.5% upside)
Key Stats
- Today's Range
- $5.88 – $6.39
- 50-Day Range
- $4.36 – $8.53
- 52-Week Range
- $4.36 – $14.06
- Volume
- 1.30 million shs
- Average Volume
- 1.42 million shs
- Market Cap
- $319.43 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.94
- Price / Sales
- 0.41
Short Interest
- Short Interest
- 2.39%
- Days to Cover
- 4.40
Financials (TTM)
- Revenue
- $770.20 million
- Net Income
- $-176,800,000
- Net Margin
- -22.96%
- Return on Equity
- -51.79%
- Debt-to-Equity
- 1.73
About Emergent Biosolutions, Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Related Stocks
Compare head-to-head: EBS vs LLY·EBS vs JNJ·EBS vs ABBV·EBS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.